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The suprachoroidal outflow pathway has the potential to reduce the intraocular pres-
sure (IOP) dramatically, as the pressure gradient between the anterior chamber and 
the suprachoroidal space/uveal capillaries (colloidal osmotic pressure) permits flow 
even when IOP is very low. Compared with trabecular bypass minimally invasive 
glaucoma surgery (MIGS) devices, suprachoroidal MIGS harnesses a pathway that 
has a much greater IOP-lowering potential as suprachoroidal aqueous drainage is 
not dependent on the episcleral venous pressure. However, this pathway has a higher 
risk of severe and prolonged hypotony, because of the greater pressure gradient. The 
reason that most patients do not develop severe hypotony is because of fibrosis in 
the suprachoroidal space which restricts aqueous draining from the anterior cham-
ber through the device from exiting the device into the suprachoroidal space. This 
may limit the long-term success of suprachoroidal devices [1].
8.2  Physiology of the Suprachoroidal Outflow Pathway
The natural suprachoroidal outflow pathway drains aqueous from the anterior cham-
ber to the suprachoroidal space via the ciliary muscle [2]. Though the existence of 
this drainage pathway was proposed more than a century ago, it was poorly under-
stood until monkey studies by Bill et al. in the 1960s allowed its physiology to be 
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better defined [3, 4]. Aqueous permeates through ciliary muscle, the principal site of 
outflow resistance [3, 5], to the supraciliary and suprachoroidal spaces which exert 
a negative pressure. This outflow is IOP-independent over a wide range of IOP 
(4–35 mmHg) [3, 6, 7]. Aqueous exits the eye from the suprachoroidal space via 
two distinct drainage routes: the uveoscleral route (larger molecules: from the 
suprachoroidal space through the sclera to the orbit) and the uveovortex route 
(smaller molecules: from the suprachoroidal space to the uveal capillaries and the 
vortex veins). Of the two drainage routes, the uveovortex drainage pathway is the 
predominant pathway and is dependent on the difference in the colloid osmotic 
pressure between the uveal interstitial fluid (low) and the uveal capillaries (high) as 
well as the intraocular hydrostatic pressure [3, 8].
8.3  Early Surgical Approaches
It is surgically possible to bypass the ciliary muscle pathway, described above, by 
disrupting the attachment of the ciliary body to the scleral spur, hence allowing 
aqueous to flow directly between the anterior chamber and the suprachoroidal space. 
In 1905, Heine described a technique of cyclodialysis performed ab externo through 
the sclera using a spatula [9, 10]. Modifications of the technique were proposed in 
the twentieth century to prevent closure of the cleft, including the implantation of 
tissue or other material [11–13].
Unfortunately, these techniques caused significant ocular trauma and their effi-
cacy in lowering the IOP was unpredictable with a high proportion of eyes develop-
ing prolonged hypotony followed by significant IOP spikes after spontaneous cleft 
closure, hence they were abandoned. Moreover, complications including supracho-
roidal haemorrhage, hyphaema and secondary cataract were frequent. Nevertheless, 
this pathway is still unique in its impressive IOP-lowering potential, hence various 
modifications in the surgical technique of trabeculectomy [14, 15], non-penetrating 
glaucoma surgery [16] and glaucoma drainage devices [17] have been proposed 
over the years in vain attempts to utilize suprachoroidal drainage in addition to 
external filtration. Although these modifications did not result in higher complica-
tion rates compared with the conventional surgical techniques, neither did they 
improve efficacy.
8.4  Ab-Externo Suprachoroidal Devices
To avoid the complications associated with excessive filtration, some means of con-
trolling the rate of aqueous outflow to the suprachoroidal space is required. Hence, 
several ab-externo suprachoroidal devices have been introduced, pioneered by the 
Gold Glaucoma Shunt (GGS, SOLX Ltd., Waltham, MA, USA) and followed by the 
STARflo Glaucoma Implant (iSTAR Medical, Isnes, Belgium) and the Aquashunt 
(OPKO Health Inc., Miami, FL, USA). Despite a sophisticated design incorporating 
flow control to prevent early hypotony with the GGS, long-term efficacy was poor 
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as fibrosis and encapsulation developed around the device [18, 19]. Conjunctival 
peritomy and scleral flap dissection are also required in order to implant such ab- 
externo suprachoroidal devices, which added to the risk of scarring and, addition-
ally, there was a concern that the GGS might also result in significant corneal 
endothelial cell loss because of its positioning. Hence, this has led to the develop-
ment of ab-interno suprachoroidal MIGS devices, which are conjunctiva-sparing 
and less invasive.
8.5  Ab-Interno Suprachoroidal MIGS Devices
The emergence of MIGS has revolutionized glaucoma surgery [20]. The high safety 
profile of MIGS permits earlier use of surgery in the glaucoma treatment algorithm. 
Ab interno suprachoroidal MIGS devices are implanted through a corneal incision, 
hence spare the conjunctiva. Compared with ab-externo suprachoroidal devices, the 
potential advantages of accessing the suprachoroidal space with an ab-interno 
MIGS device are obvious, including less trauma, better safety profile  and less 
inflammation and scarring. However, as with ab-externo suprachoroidal devices, 
the long-term efficacy of ab-interno devices may also be limited by scarring in the 
suprachoroidal space.
8.5.1  CyPass Micro-Stent
The CyPass Micro-Stent (Alcon Laboratories, Inc., Fort Worth, Texas, USA) was 
the first commercially available suprachoroidal MIGS device (Fig. 8.1). Originally 
developed by Transcend Medical, the CyPass Micro-Stent was a 6.35-mm polyam-
ide tube with a 430-μm external diameter and a 300-μm lumen. After implantation 
into the suprachoidal space, it permitted unrestricted flow between the anterior 
chamber and the suprachoroidal space. The CyPass Micro-Stent had fenestrations 
(76-μm pores) along its length, to facilitate additional lateral flow and three reten-
tion rings at the proximal end, which acted as reference points for device position 
during implantation.
8.5.1.1  Surgical Technique
The CyPass Micro-Stent was inserted ab interno into the suprachoroidal space via 
a clear corneal incision. First, the device was loaded onto the retractable guidewire 
of the applier, assuming the same curvature as the applier guidewire, thereby facili-
tating insertion into the suprachoroidal space along the scleral contour. To obtain a 
good view of the anterior chamber angle, the patient’s head was tilted away from the 
surgeon and the microscope tilted towards the surgeon. The device was inserted via 
a 20-gauge corneal incision diametrically opposite to the implantation site after 
pharmacological miosis and filling the target area with cohesive viscoelastic. The 
goniolens was placed on the cornea and the applier inserted through the corneal 
incision (Fig.  8.2). The blunt tip of the applier guidewire was slowly advanced 
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between scleral spur and ciliary body, ensuring no iris movement when entering the 
angle. If the guidewire was inserted into the correct tissue plane and, if the insertion 
angle were correct, very little resistance would be encountered when inserting the 
device between ciliary body and sclera. The curvature of the applier guidewire per-
mitted the CyPass Micro-Stent to advance along the scleral curvature. Once the 
CyPass Micro-Stent was at the correct depth, depression of the release button 
allowed the guidewire to retract. Ideally, the device was positioned so that the rim 
of the collar was at the upper border of the trabecular meshwork. After implantation 
of the CyPass Micro-stent, the viscoelastic was removed completely and the corneal 
incision sealed by hydration. A demonstration of the technique is available online 
(www.youtube.com/watch?v=_WXNL0CoJws&list=UUnkpnhwaQCC4Ary7gIyX
RIw&index=2, accessed 2nd November 2019).
Poor Visualization of the Anterior Chamber Angle
Good visualization of the anterior chamber angle during implantation was impor-
tant, though less critical than with trabecular meshwork stents as the target 
a
b
Fig. 8.1 (a) A CyPass Micro-Stent in a good position on gonioscopy in the operating theatre at the 
end of surgery. Note the blood outlining Schlemm’s canal demonstrating that the collar of the 
CyPass Micro-Stent is sitting at the level of trabecular meshwork, well away from cornea and the 
entry of the CyPass Micro-Stent into the ciliary body band, peripheral to iris root (copyright 
Moorfields Eye Hospital and Keith Barton, reproduced with permission). (b) A well-positioned 
and patent CyPass Micro-Stent visible on gonioscopy a number of weeks after surgery (Copyright 
Moorfields Eye Hospital and Keith Barton; reproduced with permission)
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implantation site, the ciliary body band is, on account of its position as the most 
posterior structure in the angle before the iris root, harder to miss. The CyPass was 
approved for implantation in eyes with open-angle glaucoma (Shaffer grade 3 or 4).
Resistance Encountered During Implantation
If resistance was encountered when advancing the device, this was either due to 
failure of the device to follow the scleral curvature or positioning of the tip of the 
guidewire in iris or ciliary body rather than between ciliary body and sclera. If the 
angulation and position of the applier were corrected, the device could be implanted 
in the suprachoroidal space with very little resistance.
Position of Device Too Anterior
If the proximal end of the CyPass Micro-Stent was positioned more anterior than 
the ideal position (rim of the collar at the level of the trabecular meshwork) (Fig. 8.3), 
the guidewide tube of the applier could be used to gently push the device deeper into 
the suprachoroidal space.
Position of Device Too Posterior
If the CyPass Micro-Stent was pushed too far into the suprachoroidal space, then 
there was a higher risk of post-operative device occlusion by iris. Sometimes the 
a
b
Fig. 8.2 (a, b) Insertion of the CyPass Micro-Stent in Fig. 8.1 (Copyright Moorfields Eye Hospital 
and Keith Barton; reproduced with permission)
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device could then be grasped carefully with retinal micro-forceps and pulled gently 
forwards into the anterior chamber. If the CyPass Micro-Stent were implanted so 
posteriorly that the tip of its collar could not be visualized, the device would have to 
be abandoned and left in the supra-choroidal space as attempted removal would 
cause excessive trauma. Implantation of a second CyPass Micro-Stent in the same 
eye would then generally be performed at least 2 clock-hours away from the first, in 
order to avoid the creation of a cyclodialysis cleft between the devices.
8.5.1.2  Mechanism of Action
Ultrasound biomicroscopy [21] and optical coherence tomography (OCT) [22] 
studies have shown that aqueous accumulated in the suprachoroidal space around 
and posterior to the CyPass Micro-Stent. In addition, as the device resumed a 
straight configuration after guidewire retraction, this created a fluid-filled space 
between the device and the sclera (tenting). Ultrasound biomicroscopy imaging of 
the suprachoroidal lake has shown that it could extend 360° circumferentially 
around the eye after CyPass Micro-Stent implantation. However, the fluid around 
and posterior to the device, as well as the space between the device and the sclera 
reduced with time, due to fibrosis in the suprachoroidal space. Given the ease with 
which choroidal effusions resorb with pressure elevation, it is most likely that aque-




Fig. 8.3 (a) Improperly 
positioned CyPass 
Micro-Stent protruding 
anteriorly and abutting 
cornea 2 years after 
surgery (copyright 
Moorfields Eye Hospital 
and Keith Barton, 
reproduced with 
permission). (b) The same 
CyPass Micro-Stent as (a), 
demonstrating that three 
rings are visible and the 
collar is very close to the 
cornea on gonioscopy, with 
a consequent high risk of 
corneal endothelial cell 
loss (Copyright Moorfields 
Eye Hospital and Keith 
Barton; reproduced with 
permission)
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8.5.1.3  Efficacy
The safety and efficacy of the CyPass Micro-Stent have been investigated in several 
clinical studies, including one large randomized controlled trial.
Hoeh et al. [23] reported the 6-month outcomes of combined cataract surgery 
and CyPass Micro-Stent implantation in an exploratory multi-centre case series of 
98 patients. The patients were divided into two groups based on whether their base-
line IOP was uncontrolled (IOP  ≥  21  mmHg, Cohort 1) or controlled 
(IOP < 21 mmHg, Cohort 2). In uncontrolled patients (n = 57), the mean IOP was 
decreased by 37% (p < 0.001) and the mean number of glaucoma medications was 
reduced by more than 50% (p < 0.001) at 6 months. Patients whose IOP was con-
trolled at baseline (n  =  41) had a 71% reduction in the number of glaucoma 
medications.
A similar study by Höh et al. [24] reported the 2-year outcomes of combined 
cataract surgery and CyPass Micro-Stent implantation, with the patients again 
divided into those with uncontrolled baseline IOP (n = 23, IOP ≥ 21 mmHg, Cohort 
1) and those with controlled baseline IOP (n = 59, IOP < 21 mmHg, Cohort 2). The 
IOP at 24 months was 15.8 ± 3.8 mmHg (37 ± 19% decrease from baseline IOP) and 
16.1 ± 3.2 mmHg (0 ± 28% decrease from baseline IOP) in Cohort 1 and Cohort 2, 
respectively. The mean number of glaucoma medications at 24  months was 
1.0 ± 1.1 in Cohort 1 and 1.1 ± 1.1 in Cohort 2. Fifteen subjects (11%) required 
additional incisional glaucoma surgery.
Garcia-Feijoo et al. [25] reported the results of the DUETTE study, a single-arm 
multi-centre study which examined the efficacy and safety of CyPass Micro-Stent 
implantation as a solo procedure in patients with medically uncontrolled POAG. Of the 
65 patients recruited, 12-month data were available for 55 patients. At 12 months, there 
was a significant decrease in the mean IOP (16.4 ± 5.5 mmHg vs. 24.5 ± 2.8 mmHg, 
p < 0.001) and the mean number of glaucoma medications (1.4 ± 1.3 vs. 2.2 ± 1.1, 
p  =  0.002). Nine patients required secondary incisional glaucoma surgery and two 
patients underwent implantation of a second Cypass Micro-Stent.
Vold et al. [26] reported the 2-year results of the COMPASS study (n = 505), a 
randomized comparative trial comparing stand-alone cataract surgery (control group, 
n = 131) with combined cataract surgery and CyPass Micro-Stent implantation (mic-
rostent group, n = 374). At baseline, both groups had similar mean IOP (24.5 ± 3.0 in 
the control group and 24.4 ± 2.8 mmHg in the microstent group, p > 0.05) and mean 
number of medications (1.3 ± 1.0 in the control group and 1.4 ± 0.9 in the microstent 
group, p > 0.05). At 2 years, a greater percentage of patients in the microstent group 
achieved ≥20% reduction in unmedicated IOP compared with the control group 
(77% vs. 60%, p < 0.001). The mean IOP reduction was 7.4 mmHg when combined 
surgery was performed and 5.4 mmHg when cataract surgery was performed as a 
standalone procedure (p < 0.001). At 2 years, 59% of the patients in the control group 
did not require any glaucoma medications compared to 85% of the patients in the 
microstent group. Three patients from the microstent group and four patients from 
the control group required further glaucoma surgery.
8 Suprachoroidal MIGS Devices
112
8.5.1.4  Complications
As a minimally invasive and blebless glaucoma surgical procedure, the CyPass 
Micro-Stent had a better safety profile than conventional glaucoma procedures such 
as trabeculectomy and tube shunts. The post-operative care was also less intense 
than that after the above procedures [27]. However, compared with trabecular 
bypass MIGS procedures, the CyPass Micro-Stent was associated with potentially 
more severe complications.
Intra-operative Complications
Serious intraoperative complications were rare with the CyPass. Typically a minor 
amount of bleeding might occur if the tip of the guidewire engaged the anterior 
chamber angle in an insufficiently peripheral position, catching the iris root. It was 
rare for bleeding to impede visualization for implantation but, when it did, injection 
of additional viscoelastic into the anterior chamber was usually sufficient to improve 
the view. There was also the possibility of inadvertent lens or corneal damage dur-
ing implantation.
Significant lateral movement of the applier or an excessively traumatic implanta-




The incidence of early post-operative inflammation (within the first month) after 
CyPass Micro-Stent implantation has been reported to be around 4.2–8.6% and 
resolved in all cases without any sequelae [25, 26]. Hoeh et al. observed late-onset 
inflammation in 3.7% (n = 5) of his patients [28], whereas Kerr et al. reported 10% 
(n  =  2), in theirs [29]. Notably, the two patients with late-onset inflammation 
reported by Kerr et al. had a history of uveitis.
Eyes with early or late-onset post-operative inflammation require an increased 
frequency of topical steroids, which can be titrated according to the severity of 
inflammation and may be necessary for several months. The IOP should be moni-
tored closely in these eyes to identify and treat steroid responsiveness.
Hypotony
When post-operative hypotony occurred with the Cypass, it was the result of aque-
ous flow into the suprachoroidal space through the CyPass Micro-Stent or around 
the device (cyclodialysis cleft).
In the COMPASS study, hypotony occurred in 11 subjects (2.9%) undergoing 
combined CyPass Micro-Stent implantation with cataract surgery, with three cases 
considered clinically significant (i.e. associated with early maculopathy). Hypotony 
was transient in all 11 subjects and resolved spontaneously. Seven subjects in the 
microstent group developed a cyclodialysis cleft exceeding 2 mm, but none developed 
hypotony and did not require re-operation, so clearly were not functional clefts [26].
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Hoeh et al. observed transient early hypotony in 13.8% of patients undergoing 
combined CyPass Micro-Stent implantation and cataract surgery. With the excep-
tion of one patient who took 6 months to resolve, the hypotony resolved spontane-
ously by 1 month [23]. Hoeh et al. also reported early hypotony in 14% of subjects 
undergoing combined CyPass Micro-Stent implantation and cataract surgery in 
another series, with all cases resolving spontaneously without visual sequelae or 
further surgical intervention [28]. A study reporting 2-year outcomes for CyPass 
Micro-Stent implantation in conjunction with cataract surgery found a similar inci-
dence of early transient hypotony (15.4% of eyes), also resolving spontaneously in 
all cases [24].
When post-operative hypotony occurred after CyPass Micro-Stent implantation, 
the frequency of topical steroids would be reduced to encourage suprachoroidal 
fibrosis around the device. Rarely, hypotony persisted or was associated with hypot-
ony maculopathy or choroidal detachment. In such cases, surgical intervention was 
occasionally required to occlude the Cypass Micro-Stent. Sii et  al. [30] have 
reported two cases of persistent hypotony which were successfully treated by 
occluding the device’s lumen ab interno with a 4-0 Nylon suture (www.youtube.
com/watch?v=5zZnrSyB5vM&list=UUnkpnhwaQCC4Ary7gIyXRIw&index=11
&t=0s, accessed 2nd November 2019).
The risk of hypotony was believed to be higher in highly myopic eyes.
IOP Spikes
IOP elevation in the immediate post-operative period (up to 48 h after the surgery) 
was most often due to retained viscoelastic and could be remedied by posterior lip 
pressure on the corneal incision using a hypodermic needle at the slit-lamp or medi-
cation. Less commonly, IOP elevation in the immediate post-operative period may 
have been due to occlusion with blood or iris. An IOP spike after the second or third 
postoperative week could be due to steroid responsiveness or occlusion of the 
implant or surrounding cleft with fibrosis (or both).
In the COMPASS study, 16 subjects in the microstent group (4.3%) developed 
transient IOP spikes, defined as IOP ≥ 10 mmHg above baseline values. All cases 
resolved, although three subjects required additional glaucoma surgical intervention 
for IOP control [26]. The frequency of transient IOP spikes was 10.5% in a study by 
Hoeh et  al. [23] and 10.8% in a study by García-Feijoó et  al. (defined as 
IOP > 30 mmHg that resolved either on its own or by adding glaucoma medications) 
[25]. Kerr et al. reported a higher rate of transient post-operative IOP spikes, occur-
ring in 20% of subjects. Fortunately, none of these subjects required further glau-
coma surgery or experienced a deterioration in best-corrected visual acuity 
(BCVA) [29].
Hyphaema
The frequency of post-operative hyphaema was reported at between 1.5% and 15%, 
with all cases resolving spontaneously within the first month [24–26, 28, 29].
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Deterioration in Vision (Loss of ≥2 Lines of BCVA)
After CyPass Micro-Stent implantation, 1.1–3.1% of patients lost ≥2 lines of BCVA 
[25, 26, 28]. The causes of the vision loss included cystoid macular oedema, cata-
ract progression (in phakic patients who underwent CyPass Micro-Stent implanta-
tion as a solo procedure), corneal oedema or posterior capsular opacification, with 
the management directed at each cause (e.g. cataract surgery, YAG laser 
capsulotomy).
Device Occlusion
Occlusion of the CyPass Micro-Stent with peripheral anterior synechiae (PAS) 
occurred in 2.1% of subjects in the COMPASS study [26]. García-Feijoó et  al. 
reported that the device was occluded by PAS in two subjects (3.1%), and Nd:YAG 
laser was successfully used to clear the occlusion in one subject [25]. Hoeh et al. 
reported partial or complete device obstruction in nine subjects (5.4%), of which the 
device was occluded by PAS in two [28]. They also reported that occlusion occurred 
within the first 3 months in 80% of the 12 subjects (8.8%) in whom the CyPass 
Micro-Stent was occluded and was usually due to excessively posterior implanta-
tion of the device [24].
Device Malposition
Device malposition occurred in two patients and device migration/dislodgement 
occurred in two patients in the COMPASS study [26]. Hoeh et al. reported that one 
subject with an anteriorly positioned CyPass Micro-Stent required additional sur-
gery to push the device further into the suprachoroidal space [23]. Kerr et  al. 
reported that, in the hands of an experienced surgeon, device re-positioning can 
easily be performed at the slit lamp with a 30-gauge needle [29]. If the position of 
the CyPass Micro-Stent was too anterior after the surgery, it should be re-positioned 
as soon as possible before fibrosis and encapsulation develops.
Conversely, if the CyPass Micro-Stent was implanted too posteriorly in the 
suprachoroidal space, there was a higher risk of device occlusion by iris or PAS [28].
Additional Glaucoma Surgery
In the COMPASS study, three subjects (0.8%) in the microstent group required 
additional glaucoma surgery to control the IOP [26]. A higher glaucoma re- operation 
rate was reported by García-Feijoó et al., with 11 subjects (16.9%) requiring addi-
tional glaucoma surgery, mostly within the first 6 months. A second CyPass Micro- 
Stent was implanted in two subjects and the remaining nine subjects required 
subsequent trabeculectomy [25]. Hoeh et al. also reported that additional glaucoma 
surgery was required in 11.0% [15] subjects [28]. The COMPASS study included 
subjects with mild to moderate POAG on 1.4 ± 0.9 glaucoma medications at base-
line, many of whom were medically controlled prior to medication washout [26]. 
On the other hand, in the study by Garcia-Feijoo et al., the mean number of glau-
coma medicines at baseline was 2.2 ± 1.1, and all subjects were medically uncon-
trolled [25].
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Corneal Endothelial Cell Loss and Corneal Decompensation
The COMPASS-XT study (a post-approval extension of the randomized clinical 
COMPASS trial) showed that patients who had undergone combined CyPass Micro- 
Stent implantation with phacoemulsification had a significantly greater reduction in 
endothelial cell counts than patients who had phacoemulsification alone, 5 years 
after surgery. Based on these findings, Alcon, the manufacturer, voluntarily with-
drew the CyPass Micro-Stent from the global market in August 2018 (www.alcon.
com/cypass-recall-information). The extent of endothelial cell loss in the 
COMPASS-XT study correlated with the number of retention rings visible on goni-
oscopy, hence the associated corneal damage was almost certainly a consequence of 
the device position in the angle. Endothelial cell loss was more prominent when two 
or more retention rings were visible in the anterior chamber. Though none of the 
patients developed clinically evident corneal decompensation, this was of concern 
because the US Food and Drug Administration (FDA) restricts the use of the CyPass 
Micro-Stent to adult patients with mild-to-moderate open-angle glaucoma in con-
junction with cataract surgery. The safety of the device is particularly important in 
this group of patients who are conventionally treated with glaucoma medication. If 
the CyPass Micro-Stent should become available again in the future, it is likely that 
the manufacturer’s directions on the surgical implantation technique would be 
amended to recommend a more posterior positioning, specifying that the device 
should not protrude, ideally above the trabecular meshwork or at worst, the 
Schwalbe’s line. It would be less likely for significant endothelial cell loss to occur 
in these circumstances. Alcon may also consider extending the indication for the 
CyPass Micro-Stent to more refractory cases of glaucoma.
In an earlier study, Hoeh H et al. reported that the incidence of contact between 
the CyPass Micro-Stent and corneal endothelium was 1.2%, as a consequence of 
anterior device placement. None of these subjects experienced visual loss or 
required additional surgery, albeit with a short follow-up of 294 ± 121 days [28]. In 
another study by Höh H et al., device–corneal endothelial contact occurred in 3.7% 
of subjects [24].
If the CyPass Micro-Stent was positioned too anteriorly or if contact is detected 
between the device and the corneal endothelium, it was advisable to re-position the 
device in the early postoperative period. Within a few weeks, fibrosis develops 
around the device, preventing it from being easily re-positioned or removed. In such 
circumstances, the CyPass Micro-Stent could be trimmed using 23 gauge vitrec-
tomy scissors, so that it does not protrude beyond the Schwalbe’s line (www.you-
tube.com/watch?v=mRHdplofoBM&list=UUnkpnhwaQCC4Ary7gIyXRIw&inde
x=5&t=0s, accessed 2nd November 2019).
Cataract Progression
In a multicentre, single-arm interventional study by Garcia-Feijoo et al., cataract 
progression occurred in 12.2% of phakic eyes 1 year after stand-alone CyPass 
Micro-Stent implantation [25]. Höh et al. reported that CyPass Micro-Stent implan-
tation was associated with cataract progression in 2% of phakic eyes [24].
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8.5.2  iStent Supra
The iStent Supra (Glaukos Corporation, San Clemente, CA, USA) is another ab- 
interno suprachoroidal MIGS device which has the Conformité Européene Mark 
(Fig. 8.4). It is a ridged curved tube made of heparin-coated polyethersulfone and 
titanium. The length of the iStent Supra is 4 mm, with an interior lumen diameter of 
165 μm. The mechanism of action of the iStent Supra is very similar to that of the 
CyPass Micro-Stent.
8.5.2.1  Implantation Technique
The implantation technique of the iStent Supra is similar to that described above for 
the CyPass Micro-Stent. A 1.5-mm clear corneal incision is sufficient for the inser-
tion of the iStent Supra.
8.5.2.2  Efficacy and Safety
Myers et al. [31] reported the efficacy of iStent Supra implantation combined with 
the implantation of two iStent Trabecular Micro-Bypass Stents and post-operative 
travoprost in patients with refractory open-angle glaucoma and previously failed 
glaucoma filtration surgeries. This case series reported the 4-year outcomes although 
it was originally designed to be a 5-year study. The mean unmedicated IOP at all 
visits was ≤13.7  mmHg (≥37% reduction from baseline). Among eyes without 
additional medication or surgery, ≥91% of eyes had ≥20% decrease in IOP on one 
medication compared with pre-operative medicated IOP at all post-operative visits. 
At 4 years, 97% and 98% of the eyes achieved IOP ≤15 and ≤18 mmHg respec-
tively on one medication. Additional medication was required in six eyes, and none 
of the patients required additional glaucoma surgery. The most frequent adverse 
event was cataract progression (16% of the subjects) [31].
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8.5.3  MINIject
The MINIject (iSTAR Medical, Isnes, Belgium) is the latest suprachoroidal MIGS 
device to be introduced (Fig.  8.5). Like its predecessor, the STARflo Glaucoma 
Implant (iSTAR Medical, Isnes, Belgium), the MINIject is made from STAR® mate-
rial, which comprises of soft and flexible medical-grade silicone that conforms to 
the curvature of the eye. The STAR® material is composed of an organized network 
of hollow spheres with a micro-porous, multi-channel matrix which promotes bio- 
integration of surrounding tissues into the material, with the intention of reducing 
fibrosis and scarring, hence increasing the efficacy of the device. The MINIject is 
5 mm in length and the green ring at the anterior segment of the device is used as a 
reference point for device position during implantation.
8.5.3.1  Implantation Technique
The implantation technique of the MINIject is similar to that described above for 
the CyPass Micro-Stent. The MINIject implant is preloaded in a transparent sheath 
attached to an applier handle, and sliding a wheel on the applier handle retracts the 
sheath back into the handle, leaving the device in place in the suprachoroidal space. 
Correct placement depth is achieved when the green ring is at the level of the 
scleral spur.
8.5.3.2  Efficacy and Safety
The first-in-human STAR-I trial for stand-alone MINIject implantation (Clinical- 
Trials.gov Identifier: NCT03193736) included 25 patients with mild-to-moderate 
POAG uncontrolled by topical glaucoma medications. Six-month data from the 
STAR-I trial showed a reduction in the mean ± standard error IOP (23.2 ± 0.6 vs. 
14.2 ± 0.9, p < 0.0001) and the mean ± standard deviation number of glaucoma 
medications (2.0 ± 1.1 versus 0.3 ± 0.7), with 21 patients (87.5%) being medication- 
free and 23 patients (95.8%) achieving a minimum 20% IOP reduction from base-
line. There were no serious adverse events related to the device or procedure and no 
additional glaucoma surgery was required. The mean central or peripheral corneal 
endothelial cell density was not significantly different from baseline [32]. At the 
time of writing, the 1-year data from the STAR-I trial have not been published.
Fig. 8.5 MINIject 
(Copyright iSTAR 
Medical, Isnes, Belgium; 
reproduced with 
permission)
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